{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:21:32Z","timestamp":1790266892249,"version":"4.1.0"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Vifor Pharma Switzerland SA"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This article examines the management of secondary hyperparathyroidism in non-dialysis dependent chronic kidney disease (NDD-CKD) patients in Switzerland, with a focus on optimizing bone and mineral health in CKD stages 3\u20134. The impact of vitamin D insufficiency on secondary hyperparathyroidism is discussed and current treatment options and challenges are explored. To support clinical practice, current secondary hyperparathyroidism management was analyzed, emphasizing monitoring practices for bone and mineral parameters alongside guidelines for prescribing vitamin D-based therapies. A treatment algorithm incorporating extended-release calcifediol, as well as insights from KDIGO (Kidney Disease: Improving Global Outcomes) for Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), are presented to refine therapeutic approaches.<\/jats:p>\n                  <jats:p>Key findings illustrate the absence of definitive clinical endpoints, leading to the proposed use of a 25(OH)D threshold &amp;lt;30\u2005ng\/mL (&amp;lt;75\u2005nmol\/L) to guide treatment initiation. Target 25(OH)D concentrations between 30\u2013100\u2005ng\/mL (75\u2013250\u2005nmol\/L) are advocated, with the 30\u2005ng\/mL level serving as a practical reference for CKD patients, consistent with KDIGO recommendations. While extended-release calcifediol has demonstrated biochemical efficacy in raising 25(OH)D and reducing parathyroid hormone levels, high-dose cholecalciferol has also shown efficacy, though data remain heterogeneous. These insights address the clinical relevance and provide actionable guidance for achieving and maintaining adequate vitamin D levels through the administration of extended-release calcifediol.<\/jats:p>\n                  <jats:p>This review underscores the importance of structured monitoring, evidence-based therapy initiation, and individualized care to improve bone and mineral metabolism in NDD-CKD patients, contributing to better long-term outcomes in this population.<\/jats:p>","DOI":"10.1093\/joneph\/aajaf008","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:13:20Z","timestamp":1780402400000},"page":"443-454","source":"Crossref","is-referenced-by-count":1,"title":["New insights into the management of secondary hyperparathyroidism in non-dialysis dependent chronic kidney disease: extended release calcifediol"],"prefix":"10.1093","volume":"39","author":[{"given":"Spiros","family":"Arampatzis","sequence":"first","affiliation":[{"name":"Bern Dialysis and Lindenhof Hospital Dialysis Center , Bern ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6557-8303","authenticated-orcid":false,"given":"Thomas","family":"Ernandez","sequence":"additional","affiliation":[{"name":"Service of Nephrology, Department of Medical Specialties, University Hospital of Geneva , Geneva ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Teta","sequence":"additional","affiliation":[{"name":"Nephrology and Dialysis Center , Prilly\/Lausanne ,","place":["Switzerland"]},{"name":"Service of Nephrology, Sion Hospital , Sion ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bonani","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Hospital Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argyrios","family":"Georgalis","sequence":"additional","affiliation":[{"name":"Department of Nephrology\/Dialysis, Cantonal Hospital Glarus , Glarus ,","place":["Switzerland"]},{"name":"Department of Medicine, Cantonal Hospital Graub\u00fcnden , Chur ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Flury","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Cantonal Hospital Frauenfeld , Frauenfeld ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7830-1645","authenticated-orcid":false,"given":"Antonio","family":"Bellasi","sequence":"additional","affiliation":[{"name":"Service of Nephrology, Ospedale Regionale di Lugano, Ospedale Civico, Ente Ospedaliero Cantonale , Lugano ,","place":["Switzerland"]},{"name":"Faculty of Biomedical Sciences, Universit\u00e0 Della Svizzera Italiana , Lugano ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"2026073019522150200_aajaf008-B1","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1093\/ndt\/gfac236","article-title":"Treatment of secondary hyperparathyroidism in non-dialysis CKD: an appraisal 2022s","volume":"38","author":"Ketteler","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026073019522150200_aajaf008-B2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"2026073019522150200_aajaf008-B3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11154-017-9421-4","article-title":"Secondary hyperparthyroidism: pathogenesis, diagnosis, preventive and therapeutic strategies","volume":"18","author":"Portillo","year":"2017","journal-title":"Rev Endocr Metab Disord"},{"key":"2026073019522150200_aajaf008-B4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1159\/000186364","article-title":"Parathyroid calcification as a complication of secondary hyperparathyroidism","volume":"57","author":"Ford","year":"2008","journal-title":"Nephron"},{"key":"2026073019522150200_aajaf008-B5","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/nep.12825","article-title":"Acute thyroiditis: an under-recognized complication of parathyroidectomy in end-stage renal failure patients with secondary hyperparathyroidism","volume":"22","author":"Chan","year":"2017","journal-title":"Nephrology"},{"key":"2026073019522150200_aajaf008-B6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/ARCHINTE.1990.00390140148031","article-title":"Digital clubbing as an unusual complication of the secondary hyperparathyroidism associated with atypical neutrophils: a case report","volume":"16","author":"Prodanovic","year":"2012","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2026073019522150200_aajaf008-B7","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1093\/ndt\/gfab184","article-title":"Independent effects of secondary hyperparathyroidism and hyperphosphataemia on chronic kidney disease progression and cardiovascular events: an analysis from the NEFRONA cohort","volume":"37","author":"Bozic","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026073019522150200_aajaf008-B8","doi-asserted-by":"publisher","first-page":"F253","DOI":"10.1152\/ajprenal.00302.2004","article-title":"The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism","volume":"288","author":"Rodriguez","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026073019522150200_aajaf008-B9","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1172\/jci116720","article-title":"Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients","volume":"92","author":"Fukuda","year":"1993","journal-title":"J Clin Invest"},{"key":"2026073019522150200_aajaf008-B10","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/ki.1997.41","article-title":"Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism","volume":"51","author":"Gogusev","year":"1997","journal-title":"Kidney Int"},{"key":"2026073019522150200_aajaf008-B11","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.3390\/nu10121890","article-title":"The emerging role of nutritional vitamin D in secondary hyperparathyroidism in CKD","volume":"10","author":"Lu","year":"2018","journal-title":"Nutrients"},{"key":"2026073019522150200_aajaf008-B12","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.14476\/jomp.2024.49.2.40","article-title":"Prevalence and risk factors of secondary hyperparathyroidism among CKD patients and correlation with different laboratory parameters","volume":"31","author":"Das","year":"2022","journal-title":"Mymensingh Med J"},{"key":"2026073019522150200_aajaf008-B13","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.endoen.2015.08.007","article-title":"Prevalence of secondary hyperparathyroidism in patients with stage 3 and 4 chronic kidney disease seen in internal medicine","volume":"62","author":"Bureo","year":"2015","journal-title":"Endocrinolog\u00eda y Nutrici\u00f3n (English Edition)"},{"key":"2026073019522150200_aajaf008-B14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.ekir.2020.12.036","article-title":"Testing patterns for CKD-MBD abnormalities in a sample US population","volume":"6","author":"Wetmore","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2026073019522150200_aajaf008-B15","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1093\/ckj\/sfab006","article-title":"Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease","volume":"14","author":"Xu","year":"2021","journal-title":"Clin Kidney J"},{"key":"2026073019522150200_aajaf008-B16","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3390\/nu15020336","article-title":"Real-world analysis of outcomes and economic burden in patients with chronic kidney disease with and without secondary hyperparathyroidism among a sample of the Italian population","volume":"15","author":"Barbuto","year":"2023","journal-title":"Nutrients"},{"key":"2026073019522150200_aajaf008-B17","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1681\/asn.V1161141","article-title":"Cell biology of parathyroid gland hyperplasia in chronic renal failure","volume":"11","author":"Dr\u00fceke","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"2026073019522150200_aajaf008-B18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"2026073019522150200_aajaf008-B19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4158\/ep.14.1.18","article-title":"Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease","volume":"14","author":"Andress","year":"2008","journal-title":"Endocr Pract"},{"key":"2026073019522150200_aajaf008-B20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what's changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"2026073019522150200_aajaf008-B21","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.3390\/nu14153009","article-title":"Vitamin D and secondary hyperparathyroidism in chronic kidney disease: a critical appraisal of the past, present, and the future","volume":"14","author":"Brandenburg","year":"2022","journal-title":"Nutrients"},{"key":"2026073019522150200_aajaf008-B22","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/S0272-6386(03)00905-3","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2026073019522150200_aajaf008-B23","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/ncpneph0189","article-title":"Reappraisal of 2003 NKF-K\/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients","volume":"2","author":"Monge","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"key":"2026073019522150200_aajaf008-B24","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/ki.2009.188","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"76","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"2026073019522150200_aajaf008-B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","journal-title":"Kidney Int Suppl (2011)"},{"key":"2026073019522150200_aajaf008-B26","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000450766","article-title":"Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease","volume":"44","author":"Sprague","year":"2016","journal-title":"Am J Nephrol"},{"key":"2026073019522150200_aajaf008-B27","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1159\/000369939","article-title":"Modified-release calcifediol effectively controls secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease","volume":"40","author":"Sprague","year":"2014","journal-title":"Am J Nephrol"},{"key":"2026073019522150200_aajaf008-B28","author":"Swissmedic Rayaldee\u00ae"},{"key":"2026073019522150200_aajaf008-B29","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2026073019522150200_aajaf008-B30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jsbmb.2013.12.009","article-title":"Regulation of the extrarenal CYP27B1-hydroxylase","volume":"144","author":"Adams","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2026073019522150200_aajaf008-B31","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/cjn.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026073019522150200_aajaf008-B32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2147\/ijnrd.S97637","article-title":"Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease","volume":"10","author":"Friedl","year":"2017","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"2026073019522150200_aajaf008-B33","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1111\/exd.13760","article-title":"Regulation of 25-hydroxyvitamin D-1-hydroxylase and 24-hydroxylase in keratinocytes by PTH and FGF23","volume":"27","author":"Wu","year":"2018","journal-title":"Exp Dermatol"},{"key":"2026073019522150200_aajaf008-B34","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1681\/asn.2009121293","article-title":"Forging forward with 10 burning questions on FGF23 in kidney disease","volume":"21","author":"Wolf","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2026073019522150200_aajaf008-B35","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1093\/ndt\/gfm286","article-title":"High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients","volume":"22","author":"Voormolen","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"2026073019522150200_aajaf008-B36","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1681\/asn.2005101101","article-title":"Baseline predictors of renal disease progression in the African American Study of Hypertension and Kidney Disease","volume":"17","author":"Norris","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2026073019522150200_aajaf008-B37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41581-018-0087-2","article-title":"Renal and extrarenal effects of fibroblast growth factor 23","volume":"15","author":"Vervloet","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"2026073019522150200_aajaf008-B38","doi-asserted-by":"publisher","first-page":"98","DOI":"10.2215\/cjn.12941213","article-title":"Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study","volume":"10","author":"Tentori","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026073019522150200_aajaf008-B39","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/ndt\/gfaa195","article-title":"The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation","volume":"36","author":"Tabibzadeh","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"2026073019522150200_aajaf008-B40","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2026073019522150200_aajaf008-B41","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1093\/ndt\/gfac167","article-title":"Secondary hyperparathyroidism (CKD-MBD) treatment and the risk of dementia","volume":"37","author":"Mathur","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026073019522150200_aajaf008-B42","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1007\/s11255-024-04083-9","article-title":"Associations between serum 25-hydroxyvitamin D and prognosis of chronic kidney disease: a prospective cohort study","volume":"56","author":"Mai","year":"2024","journal-title":"Int Urol Nephrol."},{"key":"2026073019522150200_aajaf008-B43","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/17446651.2017.1347501","article-title":"Extended-release calcifediol for secondary hyperparathyroidism in stage 3-4 chronic kidney disease","volume":"12","author":"Sprague","year":"2017","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2026073019522150200_aajaf008-B44","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/ndt\/gfx059","article-title":"High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD stages 3-4: results of a 12-week double-blind, randomized, controlled study","volume":"33","author":"Westerberg","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2026073019522150200_aajaf008-B45","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.jsbmb.2014.11.022","article-title":"Modified-release oral calcifediol corrects vitamin D insufficiency with minimal CYP24A1 upregulation","volume":"148","author":"Petkovich","year":"2015","journal-title":"J Steroid Biochem and Mol Biol"},{"key":"2026073019522150200_aajaf008-B46","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1159\/000098561","article-title":"Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease","volume":"27","author":"Zisman","year":"2007","journal-title":"Am J Nephrol"},{"key":"2026073019522150200_aajaf008-B47","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.2215\/cjn.02140309","article-title":"Clinical outcomes with active versus nutritional vitamin D compounds in chronic kidney disease","volume":"4","author":"Kalantar-Zadeh","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026073019522150200_aajaf008-B48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1053\/j.ajkd.2007.04.010","article-title":"Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD","volume":"50","author":"Al-Aly","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2026073019522150200_aajaf008-B49","doi-asserted-by":"publisher","first-page":"e1424","DOI":"10.1210\/clinem\/dgad289","article-title":"Paricalcitol and extended-release calcifediol for treatment of secondary hyperparathyroidism in non-dialysis chronic kidney disease: results from a network meta-analysis","volume":"108","author":"Franchi","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"2026073019522150200_aajaf008-B50","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1159\/000529523","article-title":"Evaluation of therapies for secondary hyperparathyroidism associated with vitamin D insufficiency in chronic kidney disease","volume":"9","author":"Strugnell","year":"2023","journal-title":"Kidney Dis"},{"key":"2026073019522150200_aajaf008-B51","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1159\/000538818","article-title":"Extended-release calcifediol: a data journey from phase 3 studies to real-world evidence highlights the importance of early treatment of secondary hyperparathyroidism","volume":"148","author":"Merante","year":"2024","journal-title":"Nephron"},{"key":"2026073019522150200_aajaf008-B52","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12882-022-02993-3","article-title":"Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients","volume":"23","author":"Germain","year":"2022","journal-title":"BMC Nephrol"},{"key":"2026073019522150200_aajaf008-B53","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1159\/000518545","article-title":"Real-world assessment: clinical effectiveness and safety of extended-release calcifediol","volume":"52","author":"Fadda","year":"2021","journal-title":"Am J Nephrol"},{"key":"2026073019522150200_aajaf008-B54","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s40620-021-01152-5","article-title":"Extended-release calcifediol in stage 3-4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D","volume":"35","author":"Cozzolino","year":"2022","journal-title":"J Nephrol"},{"key":"2026073019522150200_aajaf008-B55","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s40620-015-0186-0","article-title":"Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low","volume":"29","author":"Ennis","year":"2016","journal-title":"J Nephrol"},{"key":"2026073019522150200_aajaf008-B56","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s40620-021-01082-2","article-title":"Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease","volume":"34","author":"Ketteler","year":"2021","journal-title":"J Nephrol"},{"key":"2026073019522150200_aajaf008-B57","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1007\/s00198-019-05033-3","article-title":"Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease","volume":"30","author":"Geng","year":"2019","journal-title":"Osteoporos Int"},{"key":"2026073019522150200_aajaf008-B58","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1093\/ndt\/gfaa172","article-title":"Con: nutritional vitamin D replacement in chronic kidney disease and end-stage renal disease","volume":"36","author":"Agarwal","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2026073019522150200_aajaf008-B59","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1093\/ckj\/sfab035","article-title":"Impact of nutritional vitamin D supplementation on parathyroid hormone and 25-hydroxyvitamin D levels in non-\u00addialysis chronic kidney disease: a meta-analysis","volume":"14","author":"Bover","year":"2021","journal-title":"Clin Kidney J"},{"key":"2026073019522150200_aajaf008-B60","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1159\/000524289","article-title":"Extended-release rcalcifediol effectively raises serum total 25-hydroxyvitamin D even in overweight nondialysis chronic kidney disease patients with secondary hyperparathyroidism","volume":"53","author":"Bishop","year":"2022","journal-title":"Am J Nephrol"},{"key":"2026073019522150200_aajaf008-B61","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1080\/14656566.2019.1663826","article-title":"Evaluating extended-release calcifediol as a treatment option for chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"20","author":"Cozzolino","year":"2019","journal-title":"Exp Opin Pharmacother"},{"key":"2026073019522150200_aajaf008-B62","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1111\/nep.12505","article-title":"Effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2015","journal-title":"Nephrology (Carlton)"},{"key":"2026073019522150200_aajaf008-B63","doi-asserted-by":"publisher","first-page":"e61387","DOI":"10.1371\/journal.pone.0061387","article-title":"Impact of vitamin D on chronic kidney diseases in non-dialysis patients: a meta-analysis of randomized controlled trials","volume":"8","author":"Xu","year":"2013","journal-title":"PLoS One"},{"key":"2026073019522150200_aajaf008-B64","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA"},{"key":"2026073019522150200_aajaf008-B65","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1681\/asn.2013010103","article-title":"Effect of paricalcitol on left ventricular mass and function in CKD\u2013the OPERA trial","volume":"25","author":"Wang","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2026073019522150200_aajaf008-B66","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1093\/ckj\/sfab091","article-title":"Active vitamin D increases the risk of hypercalcaemia in non-dialysis chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis","volume":"14","author":"Cozzolino","year":"2021","journal-title":"Clin Kidney J"},{"key":"2026073019522150200_aajaf008-B67","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1159\/000499187","article-title":"Rationale for raising current clinical practice guideline target for serum 25-hydroxyvitamin D in chronic kidney disease","volume":"49","author":"Strugnell","year":"2019","journal-title":"Am J Nephrol"},{"key":"2026073019522150200_aajaf008-B68","author":"Federal Department of Home Affairs (FDHA)","year":"2023"},{"key":"2026073019522150200_aajaf008-B69"},{"key":"2026073019522150200_aajaf008-B70","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1038\/s41430-020-0558-y","article-title":"Vitamin D deficiency 2.0: an update on the current status worldwide","volume":"74","author":"Amrein","year":"2020","journal-title":"Eur J Clin Nutr."}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/3\/443\/68450273\/aajaf008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/39\/3\/443\/68450273\/aajaf008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:52:30Z","timestamp":1785455550000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/39\/3\/443\/8699858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":70,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6,2]]},"published-print":{"date-parts":[[2026,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajaf008","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,4]]}}}